Focused On-demand Library for Glycine receptor subunit alpha-1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for receptors.

Fig. 1. The sreening workflow of Receptor.AI

This process includes extensive molecular simulations of the receptor in its native membrane environment, along with ensemble virtual screening that accounts for its conformational mobility. In the case of dimeric or oligomeric receptors, the entire functional complex is modelled, identifying potential binding pockets on and between the subunits to encompass all possible mechanisms of action.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

P23415

UPID:

GLRA1_HUMAN

Alternative names:

Glycine receptor 48 kDa subunit; Glycine receptor strychnine-binding subunit

Alternative UPACC:

P23415; B2R6T3; Q14C77; Q6DJV9

Background:

The Glycine receptor subunit alpha-1, also known as the Glycine receptor 48 kDa subunit or the Glycine receptor strychnine-binding subunit, is a pivotal component of glycine receptors, which are ligand-gated chloride channels. These channels are essential for the regulation of neuronal excitability and play a crucial role in the generation of inhibitory postsynaptic currents. Their activation is facilitated by extracellular glycine, taurine, and beta-alanine, with channel characteristics varying based on subunit composition.

Therapeutic significance:

The Glycine receptor subunit alpha-1 is implicated in Hyperekplexia 1, a neurological disorder characterized by muscular rigidity and an exaggerated startle response. Understanding the role of this protein could lead to novel therapeutic strategies for managing this condition.